Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics
RETA Price/Volume Stats
| Current price | $172.36 | 52-week high | $172.46 |
| Prev. close | $172.32 | 52-week low | $21.83 |
| Day low | $172.32 | Volume | 1,988,500 |
| Day high | $172.46 | Avg. volume | 1,091,032 |
| 50-day MA | $158.53 | Dividend yield | N/A |
| 200-day MA | $95.04 | Market Cap | 6.58B |
RETA Stock Price Chart Interactive Chart >
Reata Pharmaceuticals, Inc. - (RETA) Company Bio
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.
Latest RETA News From Around the Web
Below are the latest news stories about REATA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RETA as an investment opportunity.
Should You Add Reata Pharmaceuticals (RETA) to Your Portfolio?TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […] |
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.PLANO, Texas, September 21, 2023--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen"). |
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near FutureReata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is possibly approaching a major achievement in its business, so we would... |
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 billion in cash. Buying Reata Pharmaceuticals will accomplish a couple of things for Biogen. First, it'll gain control of Reata's newly approved drug Skyclarys, which is the only medicine approved to treat Friedreich's ataxia. |
Insider Sell: SVP, Chief Accounting Officer Bhaskar Anand Sells 406 Shares of Reata ...On September 5, 2023, Bhaskar Anand, the SVP, Chief Accounting Officer of Reata Pharmaceuticals Inc (NASDAQ:RETA), sold 406 shares of the company. |
RETA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 72.79% |
| 3-year | 94.96% |
| 5-year | 117.82% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | 44.07% |
| 2021 | -78.67% |
| 2020 | -39.53% |
| 2019 | 264.40% |
Continue Researching RETA
Want to do more research on Reata Pharmaceuticals Inc's stock and its price? Try the links below:Reata Pharmaceuticals Inc (RETA) Stock Price | Nasdaq
Reata Pharmaceuticals Inc (RETA) Stock Quote, History and News - Yahoo Finance
Reata Pharmaceuticals Inc (RETA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...